We are live on
!
Find out more
CAM
Cresset Asset Management Portfolio holdings
AUM
$23.1B
1-Year Est. Return
27.04%
This Fund
S&P 500
This Quarter
Est. Return
+9.09%
1 Year Est. Return
+27.04%
3 Year Est. Return
+93.04%
5 Year Est. Return
+103.75%
10 Year Est. Return
–
AUM
$7.06B
AUM Growth
+$739M
(+12%)
Cap. Flow
+$195M
Cap. Flow
% of AUM
2.76%
Top 10 Holdings %
Top 10 Hldgs %
64.54%
Holding
1,102
New
171
Increased
503
Reduced
296
Closed
86
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$53M |
| 2 |
iShares Gold Trust
IAU
|
+$36.5M |
| 3 |
Vanguard Morningstar Small-Cap Value ETF
VBR
|
+$25.8M |
| 4 |
Palantir
PLTR
|
+$25.5M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$20.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARK Innovation ETF
ARKK
|
+$68.1M |
| 2 |
iShares MSCI USA Value Factor ETF
VLUE
|
+$20.3M |
| 3 |
JPMorgan Ultra-Short Income ETF
JPST
|
+$17M |
| 4 |
Invesco Preferred ETF
PGX
|
+$15.5M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$15.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 40.17% |
| 2 | Consumer Discretionary | 6.79% |
| 3 | Healthcare | 3.61% |
| 4 | Financials | 3.09% |
| 5 | Communication Services | 2.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
901
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $227K | ﹤0.01% |
+2,421
| New | +$223K |
|
|
PSXP
902
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $227K | ﹤0.01% |
+5,750
| New | +$213K |
|
903
Franco-Nevada
FNV
$45.4B
| $226K | ﹤0.01% |
+1,557
| New | +$225K |
|
904
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.6B
| $226K | ﹤0.01% |
+3,726
| New | +$223K |
|
905
Choice Hotels
CHH
$4.8B
| $224K | ﹤0.01% |
1,880
-336
| -15% | -$39.1K |
|
906
Nasdaq
NDAQ
$53.1B
| $224K | ﹤0.01% |
3,813
-1,365
| -26% | -$75.1K |
|
907
Sunrun
RUN
$2.46B
| $224K | ﹤0.01% |
+4,009
| New | +$194K |
|
908
Qiagen
QGEN
$8.75B
| $220K | ﹤0.01% |
+4,295
| New | +$222K |
|
909
Teva Pharmaceuticals
TEVA
$40.8B
| $220K | ﹤0.01% |
22,206
-258
| -1% | -$2.73K |
|
910
Public Service Enterprise Group
PEG
$37.7B
| $219K | ﹤0.01% |
+3,660
| New | +$226K |
|
911
PJT Partners
PJT
$4.41B
| $219K | ﹤0.01% |
3,068
| – | – |
|
912
Vertex
VERX
$1.93B
| $219K | ﹤0.01% |
+9,998
| New | +$203K |
|
913
ENI
E
$77.7B
| $218K | ﹤0.01% |
8,936
+250
| +3% | +$6.23K |
|
914
Eversource Energy
ES
$27.3B
| $218K | ﹤0.01% |
2,716
-389
| -13% | -$32.8K |
|
915
Vanguard Short-Term Inflation-Protected Securities Index Fund
VTIP
$19.1B
| $218K | ﹤0.01% |
4,157
-147
| -3% | -$7.66K |
|
916
Brown-Forman Class A
BF.A
$13.3B
| $217K | ﹤0.01% |
+3,068
| New | +$219K |
|
917
Ingersoll Rand
IR
$34B
| $217K | ﹤0.01% |
4,459
+171
| +4% | +$8.39K |
|
|
JMIA
918
Jumia Technologies
JMIA
$754M
| $217K | ﹤0.01% |
+7,171
| New | +$217K |
|
919
Lloyds Banking Group
LYG
$90.9B
| $217K | ﹤0.01% |
85,161
+9,150
| +12% | +$23.5K |
|
920
Mohawk Industries
MHK
$9.28B
| $217K | ﹤0.01% |
1,132
-6
| -0.5% | -$1.22K |
|
921
Principal Financial Group
PFG
$24.4B
| $217K | ﹤0.01% |
+3,438
| New | +$220K |
|
922
Darden Restaurants
DRI
$24.5B
| $216K | ﹤0.01% |
+1,479
| New | +$208K |
|
923
Dorman Products
DORM
$4.12B
| $215K | ﹤0.01% |
2,072
-346
| -14% | -$35.5K |
|
924
iShares Biotechnology ETF
IBB
$9.71B
| $214K | ﹤0.01% |
1,309
-1,149
| -47% | -$177K |
|
925
Kulicke & Soffa
KLIC
$4.76B
| $214K | ﹤0.01% |
+3,491
| New | +$188K |
|
Similar funds
CHP
FAM
OAG
BA
Cresset Asset Management's Q2 2021 Portfolio in Review
As of Q2 2021, Cresset Asset Management held 1,102 positions worth $7.06B, up 12% from $6.32B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Cresset Asset Management's Q2 2021 filing shows 171 new, 503 increased, 296 reduced and 86 closed positions. Its largest new stake was RTX Corp: 183,725 shares worth $15.7M. The largest sale was ARK Innovation ETF, an estimated $68.1M.
By sector, the portfolio is most concentrated in Technology at 40% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Cresset Asset Management's largest Q2 2021 buy was RTX Corp: 183,725 shares worth $15.7M.
- Cresset Asset Management added most to Apple in Q2 2021, an estimated $53M increase.
- Cresset Asset Management's biggest Q2 2021 reduction was ARK Innovation ETF, cutting an estimated $68.1M.
- Cresset Asset Management fully exited iShares MSCI USA Value Factor ETF in Q2 2021, selling an estimated $20.3M.
- Cresset Asset Management's ten largest holdings make up 65% of its $7.06B portfolio in Q2 2021.
- Cresset Asset Management opened 171 new positions and closed 86 in Q2 2021.
- Cresset Asset Management's portfolio value rose 12% quarter-over-quarter to $7.06B.
Based on Cresset Asset Management's 13F filing for Q2 2021, filed 10 Aug 2021.